Mesoblast Ltd
ASX:MSB

Watchlist Manager
Mesoblast Ltd Logo
Mesoblast Ltd
ASX:MSB
Watchlist
Price: 1.505 AUD 1.35% Market Closed
Market Cap: 1.7B AUD
Have any thoughts about
Mesoblast Ltd?
Write Note
MSB
/
Cash Flow Statement
/
Cash Interest Paid

Mesoblast Ltd
Cash Interest Paid

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Mesoblast Ltd
Cash Interest Paid Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Interest Paid CAGR 3Y CAGR 5Y CAGR 10Y
Mesoblast Ltd
ASX:MSB
Cash Interest Paid
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Immutep Ltd
ASX:IMM
Cash Interest Paid
-AU$20.5k
CAGR 3-Years
-16%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
CSL Ltd
ASX:CSL
Cash Interest Paid
$432m
CAGR 3-Years
39%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Clinuvel Pharmaceuticals Ltd
ASX:CUV
Cash Interest Paid
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Telix Pharmaceuticals Ltd
ASX:TLX
Cash Interest Paid
-AU$785k
CAGR 3-Years
-60%
CAGR 5-Years
-115%
CAGR 10-Years
N/A
PYC Therapeutics Ltd
ASX:PYC
Cash Interest Paid
-AU$49.4k
CAGR 3-Years
-8%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Mesoblast Ltd
Glance View

Market Cap
1.7B AUD
Industry
Biotechnology

Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. The company is headquartered in Melbourne, Victoria and currently employs 83 full-time employees. The company went IPO on 2004-12-16. The firm is using its mesenchymal lineage cell technology platform to develop and commercialize allogeneic cellular medicines to treat complex inflammatory diseases. Its product candidate includes Remestemcel-L ((RYONCIL) for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), Rexlemestrocel-L (REVASCOR) for the advanced chronic heart failure (CHF) and MPC-06-ID for the treatment of chronic low back pain caused by disc degeneration (CLBP). Its product candidate MPC-150-IM for the treatment or prevention of chronic heart failure and MPC-25-IC for the treatment or prevention of acute myocardial infarction. Its product candidate also includes MPC-300-IV for the treatment of biologic-refractory rheumatoid arthritis and diabetic nephropathy.

MSB Intrinsic Value
3.19 AUD
Undervaluation 53%
Intrinsic Value
Price
What is Intrinsic Value?

See Also

Back to Top
ALPHA SPREAD
Follow us
Join more than 201,200+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.